



Antimicrobial Agents that Interfere with Bacterial and Fungal Biofilms

Guest Editors:

Dr. Teresa Fasciana

Department of Health
Promotion, Mother and Child
Care, Internal Medicine and
Medical Specialties, University of
Palermo, 90133 Palermo, Italy

Prof. Dr. Anna Giammanco

Department of Health
Promotion, Mother and Child
Care, Internal Medicine and
Medical Specialties, University of
Palermo, 90127 Palermo, Italy

Dr. Paola Di Carlo

Department of Health
Promotion, Maternal-Childhood,
Internal Medicine of Excellence G.
D'Alessandro, University of
Palermo, 90127 Palermo, Italy

Deadline for manuscript
submissions:
closed (31 December 2022)

Message from the Guest Editors

Dear Colleagues,

The spread of multi-resistant microorganisms represents a continuous growing problem in public health. These organisms have a high potential for biofilm production, which might explain their outstanding antibiotic resistance, survival properties, and increased virulence and it is known that conventional antibiotic medications are inadequate at eradicating these biofilm-mediated infections. This situation demands new strategies for biofilm-associated infections, and currently, researchers focus on the development of antibiofilm agents that are specific to biofilms, but are nontoxic, because it is believed that this prevents the development of drug resistance.

On the basis of this evidence, this Special Issue will publish papers focusing on natural products to eliminate the biofilm-forming microorganisms and provide concise information on existing confines and recent developments in the modification of different natural anti-biofilm agents to make them effective drug candidates for clinical exploitation.

Keywords: biofilm; natural agents; MDR; bacteria; fungi





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Nicholas Dixon

School of Chemistry and
Molecular Bioscience, University
of Wollongong, Wollongong, NSW
2522, Australia

Message from the Editor-in-Chief

There are very few fields that attract as much attention as scientific endeavor related to antibiotic discovery, use and preservation. The public, patients, scientists, clinicians, policy-makers, NGOs, governments, and supra-governmental organizations are all focusing intensively on it: all are concerned that we use our existing agents more effectively, and develop and evaluate new interventions in time to face emerging challenges for the benefit of present and future generations. We need every discipline to contribute and collaborate: molecular, microbiological, clinical, epidemiological, geographic, economic, social scientific and policy disciples are all key. *Antibiotics* is a nimble, inclusive and rigorous indexed journal as an enabling platform for all who can contribute to solving the greatest broad concerns of the modern world.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q1
(*General Pharmacology, Toxicology and Pharmaceutics*)

Contact Us

Antibiotics Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/antibiotics
antibiotics@mdpi.com
[X@antibioticsmdpi](https://twitter.com/antibioticsmdpi)